06/01/23 4:15 PMNasdaq : OCX conferencesOncocyte Corporation to Present at the LD Micro Invitational XIIIOncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies,RHEA-AIneutral
05/11/23 8:00 AMNasdaq : OCX earningsOncocyte Reports First Quarter 2023 Financial ResultsOncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023. First Quarter 2023 and Recent Highlights:RHEA-AInegative
04/27/23 4:59 PMNasdaq : OCX earningsOncocyte To Announce First Quarter 2023 Financial ResultsOncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023,RHEA-AIneutral
04/18/23 8:45 AMNasdaq : OCX Oncocyte Presents New Data at AACROncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research. Four abstracts explore theRHEA-AIneutral
04/12/23 4:15 PMNasdaq : OCX Oncocyte Announces Reduction in ForceOncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforce, which management believes will extend Oncocyte’s cash runway in 2024. “As part of our effortsRHEA-AIneutral
04/07/23 8:24 AMNasdaq : OCX Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal CancerOncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial inRHEA-AIneutral
04/03/23 8:00 AMNasdaq : OCX offeringOncocyte Pricing of $13.86 Million Public Offering of Common StockOncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, announced today the entry into an agreement with certain members of the Company’s board of directors,RHEA-AIneutral
03/31/23 5:00 PMNasdaq : OCX earningsOncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-KOncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K and reports preliminary financial resultsRHEA-AIneutral
03/29/23 4:01 PMNasdaq : OCX earningsOncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings CallOncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results onRHEA-AIneutral
03/15/23 4:01 PMNasdaq : OCX earningsOncocyte to Announce Fourth Quarter and Full Year 2022 Financial ResultsOncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 financial results on Wednesday, March 29, 2023. In conjunction with the release, Oncocyte will host aRHEA-AIneutral